European Medicines Agency

Doc. Ref. EMEA/494847/2009
P/166/2009

EUROPEAN MEDICINES AGENCY DECISION

of 21 August 2009

on the refusal of a Paediatric Investigation Plan for live bacterium B. thetaiotaomicron (EMEA-000561-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended

(ONLY THE ENGLISH TEXT IS AUTHENTIC)

DISCLAIMER: This Decision does not entitle to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006, as amended.

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 70
E-mail: mail@emea.europa.eu http://www.emea.europa.eu

EUROPEAN MEDICINES AGENCY DECISION

of 21 August 2009

on the refusal of a Paediatric Investigation Plan for live bacterium B. thetaiotaomicron (EMEA-000561-PIP01-09) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council as amended

THE EUROPEAN MEDICINES AGENCY,

Having regard to the Treaty establishing the European Community,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use as amended and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by GT Biologics on 9 March 2009 under Article 16(1) of Regulation (EC) No 1901/2006 as amended,

Having regard to the Opinion of the Paediatric Committee of the European Medicines Agency, issued on 26 June 2009, in accordance with Article 18 of Regulation (EC) No 1901/2006 as amended,

Having regard to Article 25 of Regulation (EC) No 1901/2006 as amended,

WHEREAS:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the refusal of a Paediatric Investigation Plan,

(2) It is therefore appropriate to adopt a Decision refusing a Paediatric Investigation Plan.

[1] OJ L 378, 27.12.2006, p.1
[2] OJ L 136, 30.4.2004, p. 1

HAS ADOPTED THIS DECISION:

Article 1

A Paediatric Investigation Plan for live bacterium B. thetaiotaomicron, live bacteria in an enteric coated capsule, oral use, the details of which are set out in the Opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby refused.

Article 2

This decision is addressed to GT Biologics, The Rowett Institute of Nutrition and Health, Greenburn Road, Bucksburn, Aberdeen, AB21 9SB, United Kingdom.

Done at London, 21 August 2009

For the European Medicines Agency
Thomas Lönngren
Executive Director

(Signature on file)

European Medicines Agency
Pre-authorisation Evaluation of Medicines for Human Use

Doc. Ref. EMEA/PDCO/403424/2009
EMEA-000561-PIP01-09

OPINION OF THE PAEDIATRIC COMMITTEE ON THE REFUSAL OF A PAEDIATRIC INVESTIGATION PLAN

Scope of the application

Active substance(s):
Live bacterium B. thetaiotaomicron

Condition(s):
Crohn's Disease

Pharmaceutical form(s):
Live Bacteria in an Enteric Coated Capsule

Route(s) of administration:
Oral use

Name/corporate name of the PIP applicant:
GT Biologics

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, GT Biologics submitted for agreement to the EMEA on 9 March 2009 an application for a paediatric investigation plan for the above mentioned medicinal product.

The procedure started on 30 April 2009.

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 40
E-mail: mail@emea.europa.eu http://www.emea.europa.eu

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to refuse the paediatric investigation plan in accordance with Article 18 of said Regulation as the measures and the timelines are not appropriate to ensure the generation of the necessary data determining the conditions in which the medicinal product may be used to treat the paediatric population or some subsets, nor to adapt a paediatric formulation, or do not bring expected significant therapeutic benefit.

The Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The scientific conclusions and the grounds for refusal are set out in the summary report appended to this opinion.

This opinion is forwarded to the applicant and the Executive Director of the Agency, together with its appendix.

London, 26 June 2009

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman

(Signature on file)